These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35925450)

  • 41. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
    Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
    JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
    Friedman KG; Gauvreau K; Baker A; Son MB; Sundel R; Dionne A; Giorgio T; De Ferranti S; Newburger JW
    Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors of intravenous immunoglobulin resistance and coronary arterial lesions in Turkish children with Kawasaki disease.
    Türkuçar S; Yıldız K; Acarı C; Dundar HA; Kır M; Ünsal E
    Turk J Pediatr; 2020; 62(1):1-9. PubMed ID: 32253860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on the Management of Kawasaki Disease.
    Friedman KG; Jone PN
    Pediatr Clin North Am; 2020 Oct; 67(5):811-819. PubMed ID: 32888683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
    Shao S; Zhou K; Liu X; Liu L; Wu M; Deng Y; Duan H; Li Y; Hua Y; Wang C
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4210-e4220. PubMed ID: 33837779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Japanese Kawasaki Disease Scoring Systems: Are they Applicable to the Iranian Population?
    Edraki MR; Mohammadi H; Mehdizadegan N; Ghorashi M; Amoozgar H; Borzouee M; Ajami G; Keshavarz K; Dehghani E; Bahrami R
    Arch Iran Med; 2020 Jan; 23(1):31-36. PubMed ID: 31910632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous immunoglobulin-sensitive Kawasaki disease: a case report.
    Chu C; He L; Lin YX; Xie LP; Liu F
    Pediatr Rheumatol Online J; 2021 Nov; 19(1):157. PubMed ID: 34749768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of two same-manufacturer intravenous immunoglobulin for Kawasaki disease.
    Wu KL; Lin MT; Chang YJ
    J Formos Med Assoc; 2024 Apr; 123(4):517-522. PubMed ID: 38097428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting IVIG resistance in UK Kawasaki disease.
    Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA
    Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ; Jung JW
    Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
    Dhanrajani A; Chan M; Pau S; Ellsworth J; Petty R; Guzman J
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1536-1540. PubMed ID: 29287309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatobiliary risk factors for clinical outcome of Kawasaki disease in children.
    Yi DY; Kim JY; Choi EY; Choi JY; Yang HR
    BMC Pediatr; 2014 Feb; 14():51. PubMed ID: 24548331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
    Burns JC; Touma R; Song Y; Padilla RL; Tremoulet AH; Sidney J; Sette A; Franco A
    Autoimmunity; 2015 May; 48(3):181-8. PubMed ID: 25822882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
    Tajima M; Shiozawa Y; Kagawa J
    Pediatr Cardiol; 2015 Aug; 36(6):1159-65. PubMed ID: 25753685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L; He M; Wang W; Li S; Zhao G
    Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
    Baek JS; Yu JJ; Kim MJ; You J; Jun HO; Kim YH; Ko JK
    Pediatr Rheumatol Online J; 2018 Dec; 16(1):83. PubMed ID: 30594188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.